CA2536069C - Use of green porphyrins in ocular diagnosis and therapy - Google Patents
Use of green porphyrins in ocular diagnosis and therapy Download PDFInfo
- Publication number
- CA2536069C CA2536069C CA002536069A CA2536069A CA2536069C CA 2536069 C CA2536069 C CA 2536069C CA 002536069 A CA002536069 A CA 002536069A CA 2536069 A CA2536069 A CA 2536069A CA 2536069 C CA2536069 C CA 2536069C
- Authority
- CA
- Canada
- Prior art keywords
- green
- light
- porphyrin
- choroidal
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000004032 porphyrins Chemical class 0.000 title claims description 88
- 238000003745 diagnosis Methods 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 45
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
- 238000002428 photodynamic therapy Methods 0.000 abstract description 42
- 239000000975 dye Substances 0.000 abstract description 29
- 206010028980 Neoplasm Diseases 0.000 abstract description 28
- 238000002583 angiography Methods 0.000 abstract description 4
- 208000010642 Porphyrias Diseases 0.000 abstract 3
- 239000000906 photoactive agent Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 48
- 230000006378 damage Effects 0.000 description 31
- 210000001525 retina Anatomy 0.000 description 21
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 description 15
- 108010007622 LDL Lipoproteins Proteins 0.000 description 15
- 210000003161 choroid Anatomy 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 230000001427 coherent effect Effects 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 11
- 230000001678 irradiating effect Effects 0.000 description 11
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000013534 fluorescein angiography Methods 0.000 description 10
- 210000001210 retinal vessel Anatomy 0.000 description 10
- 230000003902 lesion Effects 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- 239000003504 photosensitizing agent Substances 0.000 description 7
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002962 histologic effect Effects 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 241000288906 Primates Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 3
- 206010057430 Retinal injury Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000002488 pyknotic effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 230000002165 photosensitisation Effects 0.000 description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004233 retinal vasculature Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 208000016623 Choroid neoplasm Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 206010055666 Retinal neovascularisation Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000002588 choroid cancer Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940035564 duration Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000001316 polygonal cell Anatomy 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as macular degeneration, is effective using green porphyries as photoactive agents. Green porphyries are also effective in photodynamic therapy of pigmented tumors of the eye. In addition, green porphyries serve as effective dyes in ocular angiography.
Description
USE OF GREEN PORPHYRINS
IN OCULAR DIAGNOSIS AND THERAPY
This application is a division of Canadian Application Serial Number
IN OCULAR DIAGNOSIS AND THERAPY
This application is a division of Canadian Application Serial Number
2,185,644, which is the national phase applicat=ion of PCT International Application PCT/US94/02639, filed 14 March 1994.
Technical Field The invention is in the field of photodynamic therapy, specifically related to ocular conditions. More particularly, the invention concerns the use of green porphyrins in photodynamic therapeutic treatment of pigmented tumors and conditions characterized by unwanted neovasculature in the eye. Green porphyrins are also useful as dyes in ocular angiography.
Bac round Art Choroidal neovascularization leads to hemorrhage and fibrosis, with resultant visual loss in a number of eye diseases, including macular degeneration, ocular histoplasmosis syndrome, myopia, and inflammatory diseases. Age-related macular degeneration is the leading cause of new blindness in the elderly, and choroidal neovascularization is responsible for 60t of the severe visual loss in patients with this diseases.
Although the natural history of the disease is eventual quiescence and regression of the neovascularization process, this usually occurs at the cost of sub-retinal fibrosis and vision loss.
Current treatment relies on occlusion of the blood vessels using laser photocoagulation. However, such treatment requires thermal destruction of the neovascular tissue, and is accompanied by full-thickness retinal damage, as well as damage to medium and large choroidal vessels. Further, the subject is lef t with an atrophic scar and visual scotoma. Moreover, recurrences are common, and visual prognosis is poor.
Developing strategies have sought more selective closure of the blood vessels to preserve the overlying neurosensory retina. One such strategy is photodynamic therapy, which relies on low intensity light exposure of photosensitized tissues to produce photochemical effects. Photosensitizing dyes are preferentially retained in tumors and neovascular tissue, which allows for selective treatment of the pathologic tissue. As a result of the i.nvention, PDT may be used to cause vascular occlusion in tumors by damaging endothelial cells, as well as a direct cytotoxic effect on tumor cells.
Photodynamic therapy of conditions in the eye characterized by neovascularization has been attempted over the past several decades:using the conventional porphyrin derivatives such as hematoporphyrin derivative and Photofrin porfimer sodium. Problems have been encountered in this context due to interference from eye pigments. In addition, phthalocyanine has been used in photodynamic treatment.
A newer photosensitizer, a member of the group designated "green porphyrins", is in the class of compounds called benzoporphyrin derivatives (BPD). This photosensitizer has also been tested to some extent in connection with ocular conditions. For example, Schmidt, U. et al. described experiments using BPD for the -treatment of Greene melanoma (a nonpigmented tumor) implanted into rabbit eyes and achieved ne.crosis in this context (JQVS (1992) 3a:1253 Abstract 2802). Lin, C.P.
et al. describe the measurement of kinetics and distribution in retinal and choroidal vessels by fluorescence imaging using a 458 nm line from an argon-ion laser to excite BPD (IOVS (1993) 3g:1168 Abstract 2293). In addition, Lin, S.C. et al. described
Technical Field The invention is in the field of photodynamic therapy, specifically related to ocular conditions. More particularly, the invention concerns the use of green porphyrins in photodynamic therapeutic treatment of pigmented tumors and conditions characterized by unwanted neovasculature in the eye. Green porphyrins are also useful as dyes in ocular angiography.
Bac round Art Choroidal neovascularization leads to hemorrhage and fibrosis, with resultant visual loss in a number of eye diseases, including macular degeneration, ocular histoplasmosis syndrome, myopia, and inflammatory diseases. Age-related macular degeneration is the leading cause of new blindness in the elderly, and choroidal neovascularization is responsible for 60t of the severe visual loss in patients with this diseases.
Although the natural history of the disease is eventual quiescence and regression of the neovascularization process, this usually occurs at the cost of sub-retinal fibrosis and vision loss.
Current treatment relies on occlusion of the blood vessels using laser photocoagulation. However, such treatment requires thermal destruction of the neovascular tissue, and is accompanied by full-thickness retinal damage, as well as damage to medium and large choroidal vessels. Further, the subject is lef t with an atrophic scar and visual scotoma. Moreover, recurrences are common, and visual prognosis is poor.
Developing strategies have sought more selective closure of the blood vessels to preserve the overlying neurosensory retina. One such strategy is photodynamic therapy, which relies on low intensity light exposure of photosensitized tissues to produce photochemical effects. Photosensitizing dyes are preferentially retained in tumors and neovascular tissue, which allows for selective treatment of the pathologic tissue. As a result of the i.nvention, PDT may be used to cause vascular occlusion in tumors by damaging endothelial cells, as well as a direct cytotoxic effect on tumor cells.
Photodynamic therapy of conditions in the eye characterized by neovascularization has been attempted over the past several decades:using the conventional porphyrin derivatives such as hematoporphyrin derivative and Photofrin porfimer sodium. Problems have been encountered in this context due to interference from eye pigments. In addition, phthalocyanine has been used in photodynamic treatment.
A newer photosensitizer, a member of the group designated "green porphyrins", is in the class of compounds called benzoporphyrin derivatives (BPD). This photosensitizer has also been tested to some extent in connection with ocular conditions. For example, Schmidt, U. et al. described experiments using BPD for the -treatment of Greene melanoma (a nonpigmented tumor) implanted into rabbit eyes and achieved ne.crosis in this context (JQVS (1992) 3a:1253 Abstract 2802). Lin, C.P.
et al. describe the measurement of kinetics and distribution in retinal and choroidal vessels by fluorescence imaging using a 458 nm line from an argon-ion laser to excite BPD (IOVS (1993) 3g:1168 Abstract 2293). In addition, Lin, S.C. et al. described
-3-photodynamic closure. of choroidal vessels using BPD in IOVS (1993) 34:1303 Abstract 2953.
The present applicants have described treating choroidal neovascularization using BPD in several abstracts published 15 March 1993. These abstracts include Schmidt-Erfurth, U. et al.
"Photothrombosis of Ocular Neovascularization Using BPD"; Haimovici, R. et al. "Localization of Benzoporphyrin Derivative Monoacid in the Rabbit Eye"; and Walsh, A.W. et al. "Photodynamic Therapy of Experimental Choroidal Neovascularization Using BPD-MA." All of the foregoing are published in IOVS (1993) 34:1303 as abstracts 256, 255 and 254, and Moulton, R.S. et al. "Response of Retinal and Choroidal Vessels to Photodynamic Therapy Using Benzoporphyrin Derivative Monoacid", IOVS (1993) 34:1169 Abstract 58.
The green porphyrins offer advantages in their selectivity for neovasculature and in their ability to effect photodynamically mediated destruction of nonpigmented tumors of the eye.
Gonzales et al. reported photodynamic therapy of pigmented melanomas in the eye using phthalocyanine as a photoactive compound (Gonzales, Y.H. et al. (IOVS (1993) 34:891 Abstract 949). The use of BPD-MA in photodynamic treatment of the nonpigmented Greene hamster melanoma in rabbit eyes was also described by Schmidt-Erfurth, U. et al. in Ophthalmology (1994) 101:89-99. This report was presented in part at the ARVO annual meeting in Sarasota, Florida, May 1992.
Disclosure of the Invention The invention is directed to diagnosis and treatment of certain conditions of the eye using photodynamic methods and employing green porphyrins as the photoactive compounds. The green porphyrins of the invention are described in U.S. Patent Nos.
The present applicants have described treating choroidal neovascularization using BPD in several abstracts published 15 March 1993. These abstracts include Schmidt-Erfurth, U. et al.
"Photothrombosis of Ocular Neovascularization Using BPD"; Haimovici, R. et al. "Localization of Benzoporphyrin Derivative Monoacid in the Rabbit Eye"; and Walsh, A.W. et al. "Photodynamic Therapy of Experimental Choroidal Neovascularization Using BPD-MA." All of the foregoing are published in IOVS (1993) 34:1303 as abstracts 256, 255 and 254, and Moulton, R.S. et al. "Response of Retinal and Choroidal Vessels to Photodynamic Therapy Using Benzoporphyrin Derivative Monoacid", IOVS (1993) 34:1169 Abstract 58.
The green porphyrins offer advantages in their selectivity for neovasculature and in their ability to effect photodynamically mediated destruction of nonpigmented tumors of the eye.
Gonzales et al. reported photodynamic therapy of pigmented melanomas in the eye using phthalocyanine as a photoactive compound (Gonzales, Y.H. et al. (IOVS (1993) 34:891 Abstract 949). The use of BPD-MA in photodynamic treatment of the nonpigmented Greene hamster melanoma in rabbit eyes was also described by Schmidt-Erfurth, U. et al. in Ophthalmology (1994) 101:89-99. This report was presented in part at the ARVO annual meeting in Sarasota, Florida, May 1992.
Disclosure of the Invention The invention is directed to diagnosis and treatment of certain conditions of the eye using photodynamic methods and employing green porphyrins as the photoactive compounds. The green porphyrins of the invention are described in U.S. Patent Nos.
4,883,790;
4,920,143; 5,095,030; and 5,171,749. These materials offer advantages of selectivity and effectiveness when employed in protocols directed to the destruction of unwanted neovasculature and pigmented tumors. They are also particularly effective as visualizing agents in angiography of ocular blood vessels. The visualization of the compounds is enhanced by their ability to fluoresce.
Accordingly, in one aspect, the invention is directed to a method to treat conditions of the eye characterized by unwanted neovasculature, which method comprises administering to a subject in need of such treatment an amount of a green porphyrin that will localize in said neovasculature; and irradiating the neovasculature with light absorbed by the green porphyrin.
In another aspect, the invention is directed to a method to treat pigmented tumors in the eye, which method comprises administering to a subject in need of such treatment an amount of a green porphyrin that will localize in said tumor; and irradiating the tumor with light absorbed by the green porphyrin.
In still another aspect, the invention is directed to a method to observe the condition of blood vessels in the eye, which method comprises administering to a subject comprising at least one eye for which said observation is desired an amount of green porphyrin which will provide an observable amount of green porphyrin in the blood vessels of said eye, permitting sufficient time to elapse so that an observable amount of said green porphyrin resides in the eyes; and observing the blood vessels in which the green porphyrin resides.
In another aspect, the present invention provides a porphyrin dye for use with light having an irradiance of about 600 mW/cm2 to treat unwanted choroidal neovasculature, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides a green prophyrin dye for use with light having an irradiance of about 600 -4a-mW/cmz to treat age-related macular degeneration, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides use of a porphyrin dye and light having an irradiance of about 600 mW/cm2 for treatment of unwanted choroidal neovasculature, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides use of a green porphyrin dye and light having an irradiance of about 600 mW/cm2 for treatment of age-related macular degeneration, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides a method of treating unwanted choroidal neovasculature in a shortened treatment time, the method comprising the steps of: administering to a primate subject in need of such treatment an amount of a porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and irradiating the neovasculature with light at an irradiance of about 600 mW/cmz, the light being absorbed by the porphyrin dye so as to occlude the neovasculature.
In another aspect, the present invention provides a method of treating age-related macular degeneration in a primate subject having unwanted choroidal neovasculature in a shortened treatment time, the method comprising the steps of: administering to the primate subject an amount of a green porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and irradiating the neovasculature with light at an irradiance of about 600 mW/cm2, the light being absorbed by the porphyrin dye so as to occlude the neovasculature.
4,920,143; 5,095,030; and 5,171,749. These materials offer advantages of selectivity and effectiveness when employed in protocols directed to the destruction of unwanted neovasculature and pigmented tumors. They are also particularly effective as visualizing agents in angiography of ocular blood vessels. The visualization of the compounds is enhanced by their ability to fluoresce.
Accordingly, in one aspect, the invention is directed to a method to treat conditions of the eye characterized by unwanted neovasculature, which method comprises administering to a subject in need of such treatment an amount of a green porphyrin that will localize in said neovasculature; and irradiating the neovasculature with light absorbed by the green porphyrin.
In another aspect, the invention is directed to a method to treat pigmented tumors in the eye, which method comprises administering to a subject in need of such treatment an amount of a green porphyrin that will localize in said tumor; and irradiating the tumor with light absorbed by the green porphyrin.
In still another aspect, the invention is directed to a method to observe the condition of blood vessels in the eye, which method comprises administering to a subject comprising at least one eye for which said observation is desired an amount of green porphyrin which will provide an observable amount of green porphyrin in the blood vessels of said eye, permitting sufficient time to elapse so that an observable amount of said green porphyrin resides in the eyes; and observing the blood vessels in which the green porphyrin resides.
In another aspect, the present invention provides a porphyrin dye for use with light having an irradiance of about 600 mW/cm2 to treat unwanted choroidal neovasculature, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides a green prophyrin dye for use with light having an irradiance of about 600 -4a-mW/cmz to treat age-related macular degeneration, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides use of a porphyrin dye and light having an irradiance of about 600 mW/cm2 for treatment of unwanted choroidal neovasculature, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides use of a green porphyrin dye and light having an irradiance of about 600 mW/cm2 for treatment of age-related macular degeneration, the light being absorbed by the porphyrin dye.
In another aspect, the present invention provides a method of treating unwanted choroidal neovasculature in a shortened treatment time, the method comprising the steps of: administering to a primate subject in need of such treatment an amount of a porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and irradiating the neovasculature with light at an irradiance of about 600 mW/cmz, the light being absorbed by the porphyrin dye so as to occlude the neovasculature.
In another aspect, the present invention provides a method of treating age-related macular degeneration in a primate subject having unwanted choroidal neovasculature in a shortened treatment time, the method comprising the steps of: administering to the primate subject an amount of a green porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and irradiating the neovasculature with light at an irradiance of about 600 mW/cm2, the light being absorbed by the porphyrin dye so as to occlude the neovasculature.
-5-Brief Description of the Drawings . Figure 1 shows preferred forms of the green porphyrins useful in the methods of the invention.
Modes of Carrying Out the Invention The methods of the claimed invention administering to a subject a green porphyrin,-whic.h is in the class of compounds called benzoporphyrin derivatives (BPD). A BPD is a synthetic chlorin-like porphyrin with a number of structural analogues, as shown in Figure 1.
Preferably, the green porphyrin is benzoporphyrin derivative mono-acid ring A (BPD-MA), which absorbs light at-about 692 nm wavelength with improved tissue penetration properties. BPD-MA is lipophilic, a potent photosensitizer, and appears to be phototoxic to neovascular tissues and tumors.
In a preferred embodiment, the green porphyrin is prepared as a liposomal preparation or is coupled to a ligand that binds to a specific surface component of the neovasculature to improve even further its effectiveness as a photosensitizer. Preferably, the ligand comprises an antibody or an immunologically reactive fragment thereof. The capacity for selective localization of a green porphyrin can also be improved by coupling to a carrier molecule that potentially delivers higher concentrations of the green porphyrin to the target tissue.
A carrier that is appropriate for clinical use is human low-density lipoprotein (LDL). Human LDL is a physiologic serum protein rnetabolized by cells via uptake by high affinity receptors. LDL exhibits desirable characteristics as a selective carrier because LDL
metabolism is increased in tumor cells. Neoplastic tissues and neovascularization have been shown to have increased numbers of LDL receptors. Further, by
Modes of Carrying Out the Invention The methods of the claimed invention administering to a subject a green porphyrin,-whic.h is in the class of compounds called benzoporphyrin derivatives (BPD). A BPD is a synthetic chlorin-like porphyrin with a number of structural analogues, as shown in Figure 1.
Preferably, the green porphyrin is benzoporphyrin derivative mono-acid ring A (BPD-MA), which absorbs light at-about 692 nm wavelength with improved tissue penetration properties. BPD-MA is lipophilic, a potent photosensitizer, and appears to be phototoxic to neovascular tissues and tumors.
In a preferred embodiment, the green porphyrin is prepared as a liposomal preparation or is coupled to a ligand that binds to a specific surface component of the neovasculature to improve even further its effectiveness as a photosensitizer. Preferably, the ligand comprises an antibody or an immunologically reactive fragment thereof. The capacity for selective localization of a green porphyrin can also be improved by coupling to a carrier molecule that potentially delivers higher concentrations of the green porphyrin to the target tissue.
A carrier that is appropriate for clinical use is human low-density lipoprotein (LDL). Human LDL is a physiologic serum protein rnetabolized by cells via uptake by high affinity receptors. LDL exhibits desirable characteristics as a selective carrier because LDL
metabolism is increased in tumor cells. Neoplastic tissues and neovascularization have been shown to have increased numbers of LDL receptors. Further, by
-6-increasing the partitioning of the green porphyrin into the lipoprotein phase of the blood, it appears to be delivered more efficiently to the target tissue.
Because of its lipophilicity and negative charge, green porphyrins strongly interact with lipoproteins. Most preferably, the green.porphyrin is complexed with low density lipoprotein (LDL).
When injected intravenously, BPD-MA is cleared from the bloodstream with a half-life of about 10-30 minutes, with the highest tissue levels being reached in about three hours after administration by injection and declining rapidly in the first 24 hours. BPD-MA is cleared primarily via bile and feces (60k), with only 4%
being cleared via the kidneys and urine. Thus, skin photosensitivity occurs with BPD-MA only transiently, with minimal reactivity after 24 hours in in vivo models.
The green porphyrin can be administered in any of a wide variety of ways, for example, orally, parenterally, or rectally. Parenteral administration, such as intravenous, intramuscular, or subcutaneous, is preferred. Intravenous injection is especially preferred.
The dose of green porphyrin can vary widely depending on the tissue to be treated; the physical delivery system in which it is carried, such as in the form of liposomes, or whether it is coupled to a target-specific ligand, such as an antibody or an immunologically active fragment.
It should be noted that the various parameters used for effective, selective photodynamic therapy in the invention are interrelated. Therefore, the dose should also be adjusted with respect to other parameters, for example, fluence, irradiance, duration of the light used in photodynamic therapy, and the time interval between administration of the dose and the therapeutic
Because of its lipophilicity and negative charge, green porphyrins strongly interact with lipoproteins. Most preferably, the green.porphyrin is complexed with low density lipoprotein (LDL).
When injected intravenously, BPD-MA is cleared from the bloodstream with a half-life of about 10-30 minutes, with the highest tissue levels being reached in about three hours after administration by injection and declining rapidly in the first 24 hours. BPD-MA is cleared primarily via bile and feces (60k), with only 4%
being cleared via the kidneys and urine. Thus, skin photosensitivity occurs with BPD-MA only transiently, with minimal reactivity after 24 hours in in vivo models.
The green porphyrin can be administered in any of a wide variety of ways, for example, orally, parenterally, or rectally. Parenteral administration, such as intravenous, intramuscular, or subcutaneous, is preferred. Intravenous injection is especially preferred.
The dose of green porphyrin can vary widely depending on the tissue to be treated; the physical delivery system in which it is carried, such as in the form of liposomes, or whether it is coupled to a target-specific ligand, such as an antibody or an immunologically active fragment.
It should be noted that the various parameters used for effective, selective photodynamic therapy in the invention are interrelated. Therefore, the dose should also be adjusted with respect to other parameters, for example, fluence, irradiance, duration of the light used in photodynamic therapy, and the time interval between administration of the dose and the therapeutic
-7-irradiation. A11 of these parameters should be adjusted to produce significant damage to neovascular or tumor tissue without significant damage to the surrounding tissue or, on the other hand, to enable the observation of blood vessels in the eye without significant damage to the surrounding tissue. Typically, the dose of green porphyrin used is within the range of from about 0.1 to about 20 mg/kg, preferably from about 0.15-2.0 mg/kg, and even more preferably from about 0.25 to about 0.75 mg/kg.
Specifically, as the green porphyrin dose is reduced from about 2 to about 1 mg/kg, the fluence required to close choroidal neovascular tissue tends to increase, for example, from about 50 to about 100 Joules/cmZ.
After the photosensitizing green porphyrin has been administered, the choroidal neovascular tissue or tumor being treated or observed in the eye is irradiated at the wavelength of maximum absorbance of the green porphyrin, usually between about 550 and 695 nm. A
wavelength in this range is especially preferred for enhanced penetration into bodily tissues.
As a result of being irradiated, the green porphyrin in its triplet state is thought to interact with oxygen and other compounds to form reactive intermediates, such as singlet oxygen, which can cause disruption of-cellular structures. Possible cellular targets include the cell membrane, mitochondria, lysosomal membranes, and the nucleus. Evidence from tumor and neovascular models indicates that occlusion of the vasculature is a major mechanism of photodynamic therapy, which.occurs by damage to endothelial cells, with subsequent platelet adhesion, degranulation, and thrombus formation.
The fluence during the irradiating treatment can vary widely, depending on type of tissue, depth of
Specifically, as the green porphyrin dose is reduced from about 2 to about 1 mg/kg, the fluence required to close choroidal neovascular tissue tends to increase, for example, from about 50 to about 100 Joules/cmZ.
After the photosensitizing green porphyrin has been administered, the choroidal neovascular tissue or tumor being treated or observed in the eye is irradiated at the wavelength of maximum absorbance of the green porphyrin, usually between about 550 and 695 nm. A
wavelength in this range is especially preferred for enhanced penetration into bodily tissues.
As a result of being irradiated, the green porphyrin in its triplet state is thought to interact with oxygen and other compounds to form reactive intermediates, such as singlet oxygen, which can cause disruption of-cellular structures. Possible cellular targets include the cell membrane, mitochondria, lysosomal membranes, and the nucleus. Evidence from tumor and neovascular models indicates that occlusion of the vasculature is a major mechanism of photodynamic therapy, which.occurs by damage to endothelial cells, with subsequent platelet adhesion, degranulation, and thrombus formation.
The fluence during the irradiating treatment can vary widely, depending on type of tissue, depth of
-8-target tissue, and the amount of overlying fluid or blood, but preferably varies from about 50-200 Joules/cm2.
The irradiance typically varies from about 150-900 mW/cm2, with the range between about 150-600 mW/cm 2 being preferred. However, the use of higher irradiances may be selected as effective and having the advantage of shortening treatment times.
The optimum time following green porphyrin administration until light treatment can vary widely depending on the mode of administration; the form of administration, such as in the form of_liposomes or as a complex with LDL; and the type of target tissue. As a specific example, a time interval of 1-20 minutes is often appropriate for.retinalneovascular tissue, about 120 minutes is allowed for choroidal neovascular tissue, and up to about three hours may be allowed for tumors.
Thus, effective vascular closure generally occurs at times in the range of about one minute to about three hours following administration of the green porphyrin.
The time of light irradiation after administration of the green porphyrin may be important as one way of maximizing the selectivity of the treatment, thus minimizing damage to structures other than the target tissues. For a primate, it is believed that the green porphyrin begins to reach the retinal vasculature by about 7-15 seconds following administration.
Typically, the green porphyrinpersists for a period of about 5-15 minutes, depending on the dose given.
Treatment within the first five minutes following administration of the green porphyrin should generally be avoided to prevent undue damage to retinal vessels still containing relatively high concentrations of the green porphyrin.
The irradiance typically varies from about 150-900 mW/cm2, with the range between about 150-600 mW/cm 2 being preferred. However, the use of higher irradiances may be selected as effective and having the advantage of shortening treatment times.
The optimum time following green porphyrin administration until light treatment can vary widely depending on the mode of administration; the form of administration, such as in the form of_liposomes or as a complex with LDL; and the type of target tissue. As a specific example, a time interval of 1-20 minutes is often appropriate for.retinalneovascular tissue, about 120 minutes is allowed for choroidal neovascular tissue, and up to about three hours may be allowed for tumors.
Thus, effective vascular closure generally occurs at times in the range of about one minute to about three hours following administration of the green porphyrin.
The time of light irradiation after administration of the green porphyrin may be important as one way of maximizing the selectivity of the treatment, thus minimizing damage to structures other than the target tissues. For a primate, it is believed that the green porphyrin begins to reach the retinal vasculature by about 7-15 seconds following administration.
Typically, the green porphyrinpersists for a period of about 5-15 minutes, depending on the dose given.
Treatment within the first five minutes following administration of the green porphyrin should generally be avoided to prevent undue damage to retinal vessels still containing relatively high concentrations of the green porphyrin.
-9-Clinical examination and fundus photography typically reveal no color change immediately following photodynamic therapy, although a mild retinal whitening occurs in some cases after about 24 hours. Closure of choroidal neovascularization, however, is preferably confirmed histologically by the observation of damage to endothelial cells. Vacuolated cytoplasm and abnormal nuclei can become apparent as early as 1-2 hours following photodynamic therapy, with disruption of neovascular tissue typically becoming more apparent by about 24 hours after light treatment. Associated damage to the retinal pigment epithelium (RPE), pyknotic nuclei in the outer nuclear layer, and loss of photoreceptors may also be observed. However, the inner retina usually appears relatively undamaged, as shown by control studies using photodynamic therapy with BPD-MA on a normal retina and choroid showing no damage to large choroidal and retinal vessels.
Closure can usually be observed angiographically by about 40 seconds to a minute in the early frames by hypofluorescence in the treated areas.
During the later angiographic frames, a corona of hyperfluorescence begins to appear and then fills the treated area, possibly representing leakage from the .25 adjacent choriocapillaris through damaged retinal pigment epithelium in the treated area. Large retinal vessels in the treated area perfuse following photodynamic therapy, but tend to demonstrate late staining.
Minimal retinal damage is generally found on histopathologic correlation and is dependent on the fluence and the time interval after irradiation that the green porphyrin is administered. Histopathologic examination usually reveals vessel remnants in the area of choroidal neovascular tissue, but the retinal vessels typically appear nbrmal. Further, there is no indication -zo-of systemic toxicity, and cutaneous photosensitization does not appear to develop.
As a result of.the invention, photodynamic therapy can be used more selectively, relying on the low intensity light exposure of green porphyrins that have become localized within vascular tissue. Complications, suck as serous detachment and_hemorrhage, are not noted with the invention. Thus, photodynamic therapy with_a green porphyrin appears to have broad application to clinical ophthalmology in treating such diseases as age-related macular degeneration, neovascular glaucoma, and persistent disc neovascularization in diabetic retinopathy.
Photodynamic therapy using a green porphyrin can also be used advantageously to treat not only nonpigmented tumors, but also pigmented intraocular tumors such as pigmented choroidal melanomas, and other pigmented tumors of-the choroid, retina, iris or cornea.
The admi.nistered green porphyrin accumulates within the neoplastic lesion and, upon localized light exposure at an appropriate wavelength, the tumor tissue is thought to be irreversibly damaged by the- interaction with active molecular species like singlet oxygen and other radicals induced by photoactivated dye molecules. Maximal efficiency in tumor destruction, combined with minimal irritation to adjacent physiological.structures is a major benefit in the treatment of intraocular .
malignancies, in particular, choroidal tumors, which are in close contact with sensitive neuronal and vascular structures.
Light microscopic evaluation of tumors that have not been treated with photodynamic therapy show a mass of polygonal cells. Cell-.nuclei are typically vesicular with prominent nucleoli, and mitotic figures are acattered throughout the microscopic field. Tumors typically exhibit many thin-walled blood vessels, which are cylindrical in shape, are lined with intact endothelial cells, and contain few erythrocytes.
After photodynamic therapy with a green porphyrin, however, tumor blood vessels become dilated and densely packed with erythrocytes. The tumor demonstrates clotted erythrocytes within the vascular lumina. Several days later, homogeneous necrosis is typically observable throughout the_lesion. The tumor cells begin toexhibit hyperchromaticnuclei and loss of cytoplasmic features. Further, vascular structures show disintegration and endothelial cell loss.
In treating tumors, the green porphyrin dosage administered may vary widely depending on other parameters, as described above but, preferably, is within the range of 0.5 to 3 mg/kg. The radiant exposure can also range widely, depending on the pigmentation and size of.the tumor, but typically is in the range from about 60 to about 2600 J/cm2. The level of light exposure is of particular interest with respect to the time duration of the treatment.
In addition, green porphyrin can be used to observe the condition of blood vessels in the either, either alone or used in concert with other dyes such as fluorescein or indocyanine green, as described above to follow the progress of destruction choroidal neovascular or tumor tissue. In such angiographic systems, a sufficient amount of green porphyrin is administered to produce an observable fluorescent emission when excited by light, preferably light having a wavelength in the range of about 550-700 nm. Images are recorded by illuminating the eye with light in the excitation wavelength range and detecting the amount of fluorescent light emitted at the emission wavelength. A preferred camera, which both emits and receives light in the 550-700 nm range, is the TopCon 50VT camera in the Ophthalmic Imaging System (Ophthalmic Imaging System Inc_, 221 Lathrop Way, Suite 1, Sacramento CA). An alternative camera is the TopCon* camera TRC 50IA connected to the TopConImagenet System (TopCon America Corporation, 65 West Century Road, Taramus NJ).
In a preferred observation method of the invention, the green porphyrin is administered, preferably by intravenous injection of a bolus followed by a saline flush. The green.porphyrin typically reaches the retinal vasculature in about 7-15 seconds, and the early angiographic frames are recorded after the first 20 seconds, one every 3-5 seconds. Additional frames are taken periodically for about two hours. A typical protocol might call for the image to be recorded at about 40 seconds, then at SO seconds, 60 seconds, two minutes, 5 minutes, 10 minutes, 20 minutes, 40 minutes, 60 m.nutes, and two hours.
A camera is usually used to collect the emitted fluorescent light, digitize the data, and store.it for later depiction on a video screen, as a hard paper copy, or in connection with some other imaging system. while a film recording device may be used when additional dyes euch as fluorescein are being used in combination with the green porphyrin, a CCD camera (video recording device) is preferable as being able to capture emissions at higher wavelengths, thus producing greater tissue penetration. As a result, one can obtain more sophisticated information regarding the pattern and extent of vascular structures in different ocular tissue layers, giving the ability to detect the "leakiness" that is characteristic of new or inflamed blood vessels.
Further, it is preferable to use a camera that is capable of providing the excitation light, appropriately filtered to deliver only light of the desired excitation * Trade-mark wavelength range, and then to capture the emitted, fluorescent light with a receiving device, appropriately filtered to receive only light in the desired emission wavelength range.
The following examples are to illustrate but not to limit the invention.
Example 1.
Control Qf xperimental Choroidal NeovascularizatiQn Using PDT with BPD-MA/TDL at Low Irradiance Cynomolgus monkeys weighing 3-4 kg were anesthetized with an intramuscular injection of ketamine hydrochloride (20 mg/kg), diazepam (1 mg/kg), and atropine (0.125 mg/kg), with a supplement of 5-6 mg/kg of ketamine hydrochloride as needed. For topical anesthesia, proparacaine (0.5!k) was used. The pupils were dilated with 2.5t phenylephrine and 0.8t tropicamide.
Choroidal neovascularization was produced in the eyes of the monkeys using a modification of the Ryan model, in which burns are placed in the macula, causing breaks'in Bruch's membrane, with a Coherent Argon Dye Laser #920, Coherent Medical Laser, Palo Alto, CA
(Ohkuma, H. et al. Arch. Ophthalm4l. (1983) 1,U:1102-1110; Ryan, S.J. Arch Ophthalmol (1982) 100:1804-1809).
Initially, a power of 300-700 mW for 0.1 seconds was used to form spots of about 100 m, but improved rates of neovascularization were obtained with 50 spots formed using a power of about 300-450 mW for 0.1 second.
The resulting choroidal neovascularizations were observed by (1) fundus photography (using a Canon Fundus' CF-60Z camera, Lake Success, Long Island, N.Y.) (2) by fluorescein angiography (for example, by using about 0.1 ml/kg body weight of 10% sodium fluorescein via saphenous vein injection); and (3) histologic examination -by light and electron microscopy.
Immediately before use, BPD-MA was dissolved in dimethyl sulfoxide (Aldrich Chemical Co., Inc., Milwaukee, WI) at a concentration of about 4 mg/ml.
Dulbeccos phosphate buffered salt solution (Meditech, Washington, D.C.) was then added to the stock to achieve a final BPD concentration of 0.8 mg/ml. Human low-density-lipoprotein (LDL) prepared from fresh frozen plasma was added at a ratio-of 1:2.5 mg BPD-MA:LDL. The green porphyrin dye and dye solutions were protected from light at all times. After mixing, the dye preparation was incubated at 37 for 30 minutes prior to intravenous injection. The monkeys were then injected intravenously via a leg vein with 1-2 mg/kg of the BPD-MA complexed with LDL over a five-minute period, followed by a flush of 3-5 cc of normal saline.
Following this intravenous injection, the eyes of the monkeys were irradiated with 692 nm of light from .20 an argon/dye laser (Coherent 920 Coherent Medical Laser, Palo Alto, CA), using a Coherent LDS-20 slit lamp. The standard fiber was coupled to larger 400 m silica optical fiber (Coherent Medical Laser, Pal Alto, CA) to allow larger treatment spots as desired. Seventeen (17) areas of. choroidal neovascularization were treated using a 1250 gm spot. Treatment spot sizes were confirmed at the treatment plane using a Dial caliper micrometer.
Some areas of choroidal neovascularization were treated with several adjacent treatment spots to treat the whole area of choroidal neovascularization. One large choroidal neovascular membrane was treated with photodynamic the'rapy to the nasal half only.
The photodynamic irradiation treatments were carried out with a plano fundus contact lens (OGFA, Ocular Instruments, Inc., Bellvue, MA). Power was verified at the cornea by a power meter (Coherent Fieldmaster, Coherent, Auborn, CA). The fluence at each treatment spot was 50, 75, 100 or 150 Joules/cm2.
Initially, the irradiance was set at 150 mW/cmZ to avoid any thermal effect but, as the experiment proceeded, the irradiance was increased to 300 mW/cm2 or 600 mW/cm2 to reduce the treatment duration time. The time interval between injection of the green porphyrin dye and the treatment irradiating step ranged from about 1 to about 81 minutes.
A number of different combinations of parameter values were studied and are summarized below in Table 1:
TASLE 1- IRRADIANCE AT 150 mW/cm' Dura- Time tion of after Closure Number Dye Treat- Injec- by of CNV dose Fluence ment tion Angio-Treated (mg/kcr) J c 2 m'n (mins) graphy 2 2 50 5.6 18, 38 2/2 1 2 75 8.3 81 1/1 1 2 100 11.2 22 1/1 2 1 50 5.6 5, 30 0/2 3 1 100 11.2 1, 2 3/3 and 5 4 1 150 16.6 14-43 3/4 "Dye only" controls, which were exposed to dye but not to laser light, were examined in the areas of normal retina/choroid. Areas of choroidal neovascularization were examined angiographically and histologically. "Light only" controls were not performed, since the irradiances used for photodynamic therapy were well below the levels used for clinical laser photocoagulation. (In a related experiment, a minimally detectable lesion using "light-only" required an irradiance of 37 W/cm2, about 100 times the light levels used for photodynamic therapy.) Following photodynamic therapy, the monkeys were returned to an-animal care facility. No attempt was made to occlude the animals' eyes, but the room in which they were housed-was darkened overnight.
The condition of the choroidal neovasculature was followed by fundus photography, fluorescein angiography, and histologic examination. In particular, the eyes of the monkeys were examined by fluorescein-angiography acutely and at 24 hours after the -._ photodynamic therapy was given. In some cases, follow-up by fluorescein angiography was performed at 48 hours and at one week, until the eyes were harvested and the animals killed at the following time points: acutely, at 24 hours, 48 hours, and 8 days following photodynamic therapy. Animals were sacrificed with an intravenous injection of 25 mg/mg Nembutal.
To perform the histologic examination, all eyes were enucleated under deep anesthesia and fixed overnight in modified Karnovsky's fixative, and then transferred to 0.1M phosphate buffer, pH 7.2 at 4 C. Both light microscopy and electron microscopy were used for these studies. For light microscopy, tissue samples were dehydrated, embedded in epon and serially sectioned at one micron. The sections were stained with tolnizin blue and examined with an Olympus photomicroscope. For -electron microscopy, tissue samples were post-fixed in 296 osmium tetroxide and dehydrated in ethanol. Sections were stained with uranyl acetate in methanol, stained with Sato's lead stain, and examined with a Philips #CM
Closure can usually be observed angiographically by about 40 seconds to a minute in the early frames by hypofluorescence in the treated areas.
During the later angiographic frames, a corona of hyperfluorescence begins to appear and then fills the treated area, possibly representing leakage from the .25 adjacent choriocapillaris through damaged retinal pigment epithelium in the treated area. Large retinal vessels in the treated area perfuse following photodynamic therapy, but tend to demonstrate late staining.
Minimal retinal damage is generally found on histopathologic correlation and is dependent on the fluence and the time interval after irradiation that the green porphyrin is administered. Histopathologic examination usually reveals vessel remnants in the area of choroidal neovascular tissue, but the retinal vessels typically appear nbrmal. Further, there is no indication -zo-of systemic toxicity, and cutaneous photosensitization does not appear to develop.
As a result of.the invention, photodynamic therapy can be used more selectively, relying on the low intensity light exposure of green porphyrins that have become localized within vascular tissue. Complications, suck as serous detachment and_hemorrhage, are not noted with the invention. Thus, photodynamic therapy with_a green porphyrin appears to have broad application to clinical ophthalmology in treating such diseases as age-related macular degeneration, neovascular glaucoma, and persistent disc neovascularization in diabetic retinopathy.
Photodynamic therapy using a green porphyrin can also be used advantageously to treat not only nonpigmented tumors, but also pigmented intraocular tumors such as pigmented choroidal melanomas, and other pigmented tumors of-the choroid, retina, iris or cornea.
The admi.nistered green porphyrin accumulates within the neoplastic lesion and, upon localized light exposure at an appropriate wavelength, the tumor tissue is thought to be irreversibly damaged by the- interaction with active molecular species like singlet oxygen and other radicals induced by photoactivated dye molecules. Maximal efficiency in tumor destruction, combined with minimal irritation to adjacent physiological.structures is a major benefit in the treatment of intraocular .
malignancies, in particular, choroidal tumors, which are in close contact with sensitive neuronal and vascular structures.
Light microscopic evaluation of tumors that have not been treated with photodynamic therapy show a mass of polygonal cells. Cell-.nuclei are typically vesicular with prominent nucleoli, and mitotic figures are acattered throughout the microscopic field. Tumors typically exhibit many thin-walled blood vessels, which are cylindrical in shape, are lined with intact endothelial cells, and contain few erythrocytes.
After photodynamic therapy with a green porphyrin, however, tumor blood vessels become dilated and densely packed with erythrocytes. The tumor demonstrates clotted erythrocytes within the vascular lumina. Several days later, homogeneous necrosis is typically observable throughout the_lesion. The tumor cells begin toexhibit hyperchromaticnuclei and loss of cytoplasmic features. Further, vascular structures show disintegration and endothelial cell loss.
In treating tumors, the green porphyrin dosage administered may vary widely depending on other parameters, as described above but, preferably, is within the range of 0.5 to 3 mg/kg. The radiant exposure can also range widely, depending on the pigmentation and size of.the tumor, but typically is in the range from about 60 to about 2600 J/cm2. The level of light exposure is of particular interest with respect to the time duration of the treatment.
In addition, green porphyrin can be used to observe the condition of blood vessels in the either, either alone or used in concert with other dyes such as fluorescein or indocyanine green, as described above to follow the progress of destruction choroidal neovascular or tumor tissue. In such angiographic systems, a sufficient amount of green porphyrin is administered to produce an observable fluorescent emission when excited by light, preferably light having a wavelength in the range of about 550-700 nm. Images are recorded by illuminating the eye with light in the excitation wavelength range and detecting the amount of fluorescent light emitted at the emission wavelength. A preferred camera, which both emits and receives light in the 550-700 nm range, is the TopCon 50VT camera in the Ophthalmic Imaging System (Ophthalmic Imaging System Inc_, 221 Lathrop Way, Suite 1, Sacramento CA). An alternative camera is the TopCon* camera TRC 50IA connected to the TopConImagenet System (TopCon America Corporation, 65 West Century Road, Taramus NJ).
In a preferred observation method of the invention, the green porphyrin is administered, preferably by intravenous injection of a bolus followed by a saline flush. The green.porphyrin typically reaches the retinal vasculature in about 7-15 seconds, and the early angiographic frames are recorded after the first 20 seconds, one every 3-5 seconds. Additional frames are taken periodically for about two hours. A typical protocol might call for the image to be recorded at about 40 seconds, then at SO seconds, 60 seconds, two minutes, 5 minutes, 10 minutes, 20 minutes, 40 minutes, 60 m.nutes, and two hours.
A camera is usually used to collect the emitted fluorescent light, digitize the data, and store.it for later depiction on a video screen, as a hard paper copy, or in connection with some other imaging system. while a film recording device may be used when additional dyes euch as fluorescein are being used in combination with the green porphyrin, a CCD camera (video recording device) is preferable as being able to capture emissions at higher wavelengths, thus producing greater tissue penetration. As a result, one can obtain more sophisticated information regarding the pattern and extent of vascular structures in different ocular tissue layers, giving the ability to detect the "leakiness" that is characteristic of new or inflamed blood vessels.
Further, it is preferable to use a camera that is capable of providing the excitation light, appropriately filtered to deliver only light of the desired excitation * Trade-mark wavelength range, and then to capture the emitted, fluorescent light with a receiving device, appropriately filtered to receive only light in the desired emission wavelength range.
The following examples are to illustrate but not to limit the invention.
Example 1.
Control Qf xperimental Choroidal NeovascularizatiQn Using PDT with BPD-MA/TDL at Low Irradiance Cynomolgus monkeys weighing 3-4 kg were anesthetized with an intramuscular injection of ketamine hydrochloride (20 mg/kg), diazepam (1 mg/kg), and atropine (0.125 mg/kg), with a supplement of 5-6 mg/kg of ketamine hydrochloride as needed. For topical anesthesia, proparacaine (0.5!k) was used. The pupils were dilated with 2.5t phenylephrine and 0.8t tropicamide.
Choroidal neovascularization was produced in the eyes of the monkeys using a modification of the Ryan model, in which burns are placed in the macula, causing breaks'in Bruch's membrane, with a Coherent Argon Dye Laser #920, Coherent Medical Laser, Palo Alto, CA
(Ohkuma, H. et al. Arch. Ophthalm4l. (1983) 1,U:1102-1110; Ryan, S.J. Arch Ophthalmol (1982) 100:1804-1809).
Initially, a power of 300-700 mW for 0.1 seconds was used to form spots of about 100 m, but improved rates of neovascularization were obtained with 50 spots formed using a power of about 300-450 mW for 0.1 second.
The resulting choroidal neovascularizations were observed by (1) fundus photography (using a Canon Fundus' CF-60Z camera, Lake Success, Long Island, N.Y.) (2) by fluorescein angiography (for example, by using about 0.1 ml/kg body weight of 10% sodium fluorescein via saphenous vein injection); and (3) histologic examination -by light and electron microscopy.
Immediately before use, BPD-MA was dissolved in dimethyl sulfoxide (Aldrich Chemical Co., Inc., Milwaukee, WI) at a concentration of about 4 mg/ml.
Dulbeccos phosphate buffered salt solution (Meditech, Washington, D.C.) was then added to the stock to achieve a final BPD concentration of 0.8 mg/ml. Human low-density-lipoprotein (LDL) prepared from fresh frozen plasma was added at a ratio-of 1:2.5 mg BPD-MA:LDL. The green porphyrin dye and dye solutions were protected from light at all times. After mixing, the dye preparation was incubated at 37 for 30 minutes prior to intravenous injection. The monkeys were then injected intravenously via a leg vein with 1-2 mg/kg of the BPD-MA complexed with LDL over a five-minute period, followed by a flush of 3-5 cc of normal saline.
Following this intravenous injection, the eyes of the monkeys were irradiated with 692 nm of light from .20 an argon/dye laser (Coherent 920 Coherent Medical Laser, Palo Alto, CA), using a Coherent LDS-20 slit lamp. The standard fiber was coupled to larger 400 m silica optical fiber (Coherent Medical Laser, Pal Alto, CA) to allow larger treatment spots as desired. Seventeen (17) areas of. choroidal neovascularization were treated using a 1250 gm spot. Treatment spot sizes were confirmed at the treatment plane using a Dial caliper micrometer.
Some areas of choroidal neovascularization were treated with several adjacent treatment spots to treat the whole area of choroidal neovascularization. One large choroidal neovascular membrane was treated with photodynamic the'rapy to the nasal half only.
The photodynamic irradiation treatments were carried out with a plano fundus contact lens (OGFA, Ocular Instruments, Inc., Bellvue, MA). Power was verified at the cornea by a power meter (Coherent Fieldmaster, Coherent, Auborn, CA). The fluence at each treatment spot was 50, 75, 100 or 150 Joules/cm2.
Initially, the irradiance was set at 150 mW/cmZ to avoid any thermal effect but, as the experiment proceeded, the irradiance was increased to 300 mW/cm2 or 600 mW/cm2 to reduce the treatment duration time. The time interval between injection of the green porphyrin dye and the treatment irradiating step ranged from about 1 to about 81 minutes.
A number of different combinations of parameter values were studied and are summarized below in Table 1:
TASLE 1- IRRADIANCE AT 150 mW/cm' Dura- Time tion of after Closure Number Dye Treat- Injec- by of CNV dose Fluence ment tion Angio-Treated (mg/kcr) J c 2 m'n (mins) graphy 2 2 50 5.6 18, 38 2/2 1 2 75 8.3 81 1/1 1 2 100 11.2 22 1/1 2 1 50 5.6 5, 30 0/2 3 1 100 11.2 1, 2 3/3 and 5 4 1 150 16.6 14-43 3/4 "Dye only" controls, which were exposed to dye but not to laser light, were examined in the areas of normal retina/choroid. Areas of choroidal neovascularization were examined angiographically and histologically. "Light only" controls were not performed, since the irradiances used for photodynamic therapy were well below the levels used for clinical laser photocoagulation. (In a related experiment, a minimally detectable lesion using "light-only" required an irradiance of 37 W/cm2, about 100 times the light levels used for photodynamic therapy.) Following photodynamic therapy, the monkeys were returned to an-animal care facility. No attempt was made to occlude the animals' eyes, but the room in which they were housed-was darkened overnight.
The condition of the choroidal neovasculature was followed by fundus photography, fluorescein angiography, and histologic examination. In particular, the eyes of the monkeys were examined by fluorescein-angiography acutely and at 24 hours after the -._ photodynamic therapy was given. In some cases, follow-up by fluorescein angiography was performed at 48 hours and at one week, until the eyes were harvested and the animals killed at the following time points: acutely, at 24 hours, 48 hours, and 8 days following photodynamic therapy. Animals were sacrificed with an intravenous injection of 25 mg/mg Nembutal.
To perform the histologic examination, all eyes were enucleated under deep anesthesia and fixed overnight in modified Karnovsky's fixative, and then transferred to 0.1M phosphate buffer, pH 7.2 at 4 C. Both light microscopy and electron microscopy were used for these studies. For light microscopy, tissue samples were dehydrated, embedded in epon and serially sectioned at one micron. The sections were stained with tolnizin blue and examined with an Olympus photomicroscope. For -electron microscopy, tissue samples were post-fixed in 296 osmium tetroxide and dehydrated in ethanol. Sections were stained with uranyl acetate in methanol, stained with Sato's lead stain, and examined with a Philips #CM
10 transmission electron microscope.
Using the low irradiance level of 150 mW/crnZ to minimize any thermal component of the treatment, green porphyrin doses of 1-2 mg/kg of BPD-MA/LDL, and fluences of 50-150 Joules/cm~, choroidal neovascularization was effectively closed. Using the higher 2 mg/kg dose effectively closed choroidal neovascularizations at even the lowest 50 Joules/cmZ fluence. When the green porphyrin dose was decreased to 1 mg/kg of BPD-MA/LDL to minimize damage to surrounding tissues, the fluence required to effectively close choroidal neovascular tissue increased to 100 Joules/cmz. At 100 and 150 Joules/cm2, the treated choroidal neovascular tissue was angiographically closed, as shown by hypofluorescence in the area of treatment.
Prior to photodynamic therapy, the areas of choroidal neovascularization exhibited a gray sub-retinal elevation that leaked profusely on fluorescein angiography. There was no apparent color change in the treated areas either during or immediately after photodynamic treatment. However, 24 hours after the irradiating step, there was mild retinal whitening in the treated areas.
Further fluorescein angiography showed hypofluorescence in the treated areas, with no apparent filling of the associated neovascular tissues. Retinal vessels within the treated areas were perfused, but stained later. A hyperfluorescent rim at the border of the treated area was apparent in the later frames of the angiograph, and the rim then progressed to fill the treated area. Although mild staining of retinal vessels was noted angiographically, no complications, such as serous retinal detachment or hemorrhage, were noted.
On histopathologic examination of the 2 mg/kg dose samples, there was marked disruption of the treated choroidal neovascular tissue with disrupted endothelial cells. The choriocapillaris was also occluded. Although large choroidal vessels were unaffected, extravasated red blood cells were noted in the choroid. Retinal pigment epithelium (RPE) damage was noted as well with vacuolated cells, with the outer nuclear.layer demonstrating pyknotic nuclei-and disrupted architecture. No histologic abnormality of the retinal vessels was seen.
Histolopathologic examination of the 1 mg/kg dose samples showed damage to endothelial cells in the choroidal neovascular tissue, with abnormal nuclei and disrupted cytoplasm in the endothelial cells. The lumens of the vessels in the choroidal neovascular tissue were occluded by fibrin acutely and were closed by 24 hours after treatment. Closure of the choroicapillaris was also noted. At 24 hours, the retinal pigment epithelium (RPE) appeared abnormal with vacuolated cytoplasm.
Pyknotic nuclei in the inner and outer layer indicated damage secondary to the laser injury used to induce the neovascularization in this model. Retinal vessels appeared to be undamaged.
Choroidal neovascular tissue that was treated and followed for eight days showed persistent closure, as shown by hypofluorescence in the early frames of the angiogram. Histologically, the treated areas demonstrated degraded vessel lumens empty of debris. The choriocapillaris was sparse but patent in the treated area. In contrast, areas of choroidal neovascularization not treated by photodynamic therapy demonstrated branching capillaries between Bruch's membrane and the outer retina.
No adverse effects of photodynamic therapy with the green porphyrin were noted. There was no associated serous retinal detachment, retinal or sub-retinal hemorrhage, or post-treatment inflammation. Further, no adverse systemic effects of the dye administration were noted. However, the low irradiance forced treatment times to be long--about 16.6 minutes to yield 150 Joules/cm2.
ENammple 2 Control of E-xnerimental Choroidal Neovascularization Using PDT with BPD-MA/LDL at Hi.aher Irradiances To make clinical treatments shorter, additional experiments were performed using higher irradiance values. Experience with higher irradiance indicated that no thermal damage would take place-with irradiances as high as 1800 mW/cm2. Moulton et al., "Response of Retinal and Choroidal Vessels to Photodynamic Therapy Using Benzoporphyrin Derivative Monoacid", IOVS 34, 1169 (1993), Abstract 2294-58. Therefore, irradiances of 300 mW/cm2 and 600 mW/cm' were also used to treat choroidal neovascular tissue in accordance with the procedures described in Example 1. The results showed that shortened treatment times effectively closed the choroidal neovascular tissue, as indicated below in Table 2.
TABLE 2 - IRRADIANCE OVER 150 mW/cm2 Dura-tion Time Number Dye Flu- Irra- of after Clos-of CNV dose ence diance Treat- Injec- ure by Trea- (mg/ (J/ (mW/ ment tion Angio-ted kg) cm2) cm2) (mins) mins crraphy 2 1 150 300 8.3 5, 53 2/2 2 1 150 600 4.7 22, 69 2/2 Occlusion of the choroidal neovascular tissue and subjacent choriocapillaris was observed, as well as damage to the retinal pigment epithelium and outer ret',i.na.
Example 3 c'ortrol of xperimental ChQroidal Neovaecularzzation UrLq PDT with BPD-MA LipoeQmee The following experiment of photodynamic therapy using a liposomal preparation of BPD-MA was conducted to determine the optimal time interval after intravenous injection as a bolus of the BPD-MA over about 20 seconds, followed by a 3-5 cc saline flush, to begin the irradiating step. Choroidal neovascularization in cynomolgus monkeys was treated to demonstrate efficacy of the photodynamic therapy. Normal chorcid tissue was treated to assess relative damage to adjacent tissues.
The monkeys were initially injected with a green porphyrin dose of 1 mg/kg. At predeterinined time intervals following this injection, the eyes of the monkeys were irradiated with an irradiance of 600 mW/cmZ, and a fluence of 150J/cm2. The irradiating light was from an argon/dye laser (Coherent 920 Coherent Medical Laser, Palo Alto, CA) equipped with a.200 micron fiber adapted through a LaserLink*(Coherent * Medical Laser) and a split lamp delivery system (Coherent). Other than these differences, the eye membranes were treated in the same manner as described in Example I. A11 areas of zreated choroidal neovasculature for all time points after the liposomal BPD-MA injection showed whitening of the retina and early hypofluorescense on fluorescein angiography when measured one week after treatment. On histology, there was evidence of partial closure of choroidal neovasculature at the early time points, no effect at mid-time points, and more effective closure at late irradiation time points, e.g., at 80 and 100 minutes.
The normal choroid treated with the same parameters showed whitening of the retina, early hypofluorescence at all time points, and histologic Trade-mark evidence of choroicapillaris (c-c) accompanied by damage to the choroid and retina, particularly at early time points.
Example 4 lZsincr PDT with BPD-MA Liposomes at Lower Green Por-phvrin Doses Using the general procedure of Example 1, additional experiments were performed using the intravenous injection of liposomal BPD-MA at doses of 0.25, 0.5 and 1 mg/kg. Photodynamic therapy was performed with an irradiance of_600 mW/cm2 , a fluence of 150 J/ctn2, and a treatment duration of four minutes, nine seconds.
The effects of treatment were assessed by fundus photography and fluorescein angiography, and then confirmed by light and electron microscopy. Photodynamic therapy of normal choroid tissue demonstrated the effect on adjacent structures, such as the retina, while the treatment of choroid neovascular tissue demonstrated efficacy.
Table 3 below describes the lesions produced on normal choroids by administration of 0.5 mg/kg BPD-MA at time points ranging from 5 to 60 minutes:
TABLE 3 - 0.5 mg/kct, NORMAL CHOROID
Time after injection Fluorescein (min) Anaioaraphy Histologv 5 Hypofluorescence c-c and large choroidal vessel closure; outer and inner retina damage.
20 Hypofluorescence; cc closure; damage retinal vessels - to outer retina normal 40 Mild early cc open (not center hypofluorescence of lesion); outer retina damage 60 Early cc closed; outer hypofluorescence; retina damage;
-less than the 20- inner.retina fairly minute lesion good.
described above When 0.5 mg/kg BPD-MA was also used to treat choroidal neovasculature under the same conditions, marked hypofluorescence corresponding to closure of choroid neovasculature was exhibited in areas irradiated at times of 5, 20 and 40 minutes after injection. When 50 minutes after injection were allowed to elapee before photodynamic irradiation was begun, therewas less hypofluorescence and presumabl.y less effective closure.
The study was then repeated with the green porphyrin dose decreased to 0.25 mg/kg. Table.4 below describes.the lesions produced on normal choroids by treatments with 0.25 mg/kg, 600 mW/cm7, and 150 J/cm2 at time points ranging from 5 to 60 minutes:
TABLE 4 - 0,25 ma/ka, NORMAL CHOROID
Time after injection Fluorescein (min) Angiography Histoloav 10 Early c-c closure;
hypofluorescence choroidal vessel -normal; RPE
damaged; retinal vessels - normal;
mild damage to outer retina 20 Early Same as 10-minute hypofluorescence lesion above 40 Faint early Patchy cc closure;
hypofluorescence; less damage to RPE
late staining and outer retina 60 Not demonstrated No effect on cc;
mild vacuolization of RPE
When the above study was repeated using the same green porphyrin dose of 0.25 mg/kg and irradiance of 600 mW/cm2, but with a reduced fluence of 100 J/cmZ, the same angiographic and histologic pattern was exhibited as described above. However, cc was open in the 40-minute lesion. - -In the last portion of these experimente, a green porphyrin dose of 0.25 mg/kg was used to treat experimental choroidal neovascularization with an irradiance of 600 mW/cmZ and a fluence of 150 J/cm2 at elapsed time points ranging from 5 to 100 minutes. This combination of conditions caused effective cc closure with only minimal damage to the outer retina. The results are shown in Table 5 below:
TABLE 5 - 0,25 ma/kgr PDT over CNV
Time after injection Fluorescein (min ) Angioaratahv Histoloay 5 Early Partially closed hypofluorescence CNV; c-c closed;
damage to inner retina 20 Early CNV - open vessel, hypofluorescence; fibrin and clots;
less than the 5- inner retina looks minute lesion fine 30 Some Minimal effect on hypofluorescense cNV
next to CNV
Hypofluorescence; Minimal effect on questionable change CNV
35 compared to previous reaction 60 Hypofluorescence Minimal effect on CNV
80 Hypofluorescence Partial closure of CNV; retina over-CNV looks intact 100 Hypofluorescence CNV partially closed Thus, fluorescein angiography and histopathology in the above series of experiments demonstrated early hypofluorescence at early time points.
Further, the histopathology study showed partial CNV
closure at all time points after injection using 80 and 100 minutes as the post-injection interval before the irradiating treatment.
In summary, acceptable destruction of choroidal neovascular tissue at all tested doses of BPD-:MA was shown by fluorescein angiography and_histology. However, the lower doses appeared to increase selectivity, as assessed by treatment of a normal choroid. Effective choriocapillaris closure in normal choroids with minimal retinal damage was produced by irradiating at a time about 10 minutes, 20 seconds after injection of the green porphyrin at a dose of 0.25 mg/kg. By adjusting the dose, the time of irradiation after green porphyrin injection, and fluence, one can improve even further_the selectivity of the green porphyrin. However, the liposomal preparation of BPD-MA was clearly demonstrated to be a potent photosensitizer.
Using the low irradiance level of 150 mW/crnZ to minimize any thermal component of the treatment, green porphyrin doses of 1-2 mg/kg of BPD-MA/LDL, and fluences of 50-150 Joules/cm~, choroidal neovascularization was effectively closed. Using the higher 2 mg/kg dose effectively closed choroidal neovascularizations at even the lowest 50 Joules/cmZ fluence. When the green porphyrin dose was decreased to 1 mg/kg of BPD-MA/LDL to minimize damage to surrounding tissues, the fluence required to effectively close choroidal neovascular tissue increased to 100 Joules/cmz. At 100 and 150 Joules/cm2, the treated choroidal neovascular tissue was angiographically closed, as shown by hypofluorescence in the area of treatment.
Prior to photodynamic therapy, the areas of choroidal neovascularization exhibited a gray sub-retinal elevation that leaked profusely on fluorescein angiography. There was no apparent color change in the treated areas either during or immediately after photodynamic treatment. However, 24 hours after the irradiating step, there was mild retinal whitening in the treated areas.
Further fluorescein angiography showed hypofluorescence in the treated areas, with no apparent filling of the associated neovascular tissues. Retinal vessels within the treated areas were perfused, but stained later. A hyperfluorescent rim at the border of the treated area was apparent in the later frames of the angiograph, and the rim then progressed to fill the treated area. Although mild staining of retinal vessels was noted angiographically, no complications, such as serous retinal detachment or hemorrhage, were noted.
On histopathologic examination of the 2 mg/kg dose samples, there was marked disruption of the treated choroidal neovascular tissue with disrupted endothelial cells. The choriocapillaris was also occluded. Although large choroidal vessels were unaffected, extravasated red blood cells were noted in the choroid. Retinal pigment epithelium (RPE) damage was noted as well with vacuolated cells, with the outer nuclear.layer demonstrating pyknotic nuclei-and disrupted architecture. No histologic abnormality of the retinal vessels was seen.
Histolopathologic examination of the 1 mg/kg dose samples showed damage to endothelial cells in the choroidal neovascular tissue, with abnormal nuclei and disrupted cytoplasm in the endothelial cells. The lumens of the vessels in the choroidal neovascular tissue were occluded by fibrin acutely and were closed by 24 hours after treatment. Closure of the choroicapillaris was also noted. At 24 hours, the retinal pigment epithelium (RPE) appeared abnormal with vacuolated cytoplasm.
Pyknotic nuclei in the inner and outer layer indicated damage secondary to the laser injury used to induce the neovascularization in this model. Retinal vessels appeared to be undamaged.
Choroidal neovascular tissue that was treated and followed for eight days showed persistent closure, as shown by hypofluorescence in the early frames of the angiogram. Histologically, the treated areas demonstrated degraded vessel lumens empty of debris. The choriocapillaris was sparse but patent in the treated area. In contrast, areas of choroidal neovascularization not treated by photodynamic therapy demonstrated branching capillaries between Bruch's membrane and the outer retina.
No adverse effects of photodynamic therapy with the green porphyrin were noted. There was no associated serous retinal detachment, retinal or sub-retinal hemorrhage, or post-treatment inflammation. Further, no adverse systemic effects of the dye administration were noted. However, the low irradiance forced treatment times to be long--about 16.6 minutes to yield 150 Joules/cm2.
ENammple 2 Control of E-xnerimental Choroidal Neovascularization Using PDT with BPD-MA/LDL at Hi.aher Irradiances To make clinical treatments shorter, additional experiments were performed using higher irradiance values. Experience with higher irradiance indicated that no thermal damage would take place-with irradiances as high as 1800 mW/cm2. Moulton et al., "Response of Retinal and Choroidal Vessels to Photodynamic Therapy Using Benzoporphyrin Derivative Monoacid", IOVS 34, 1169 (1993), Abstract 2294-58. Therefore, irradiances of 300 mW/cm2 and 600 mW/cm' were also used to treat choroidal neovascular tissue in accordance with the procedures described in Example 1. The results showed that shortened treatment times effectively closed the choroidal neovascular tissue, as indicated below in Table 2.
TABLE 2 - IRRADIANCE OVER 150 mW/cm2 Dura-tion Time Number Dye Flu- Irra- of after Clos-of CNV dose ence diance Treat- Injec- ure by Trea- (mg/ (J/ (mW/ ment tion Angio-ted kg) cm2) cm2) (mins) mins crraphy 2 1 150 300 8.3 5, 53 2/2 2 1 150 600 4.7 22, 69 2/2 Occlusion of the choroidal neovascular tissue and subjacent choriocapillaris was observed, as well as damage to the retinal pigment epithelium and outer ret',i.na.
Example 3 c'ortrol of xperimental ChQroidal Neovaecularzzation UrLq PDT with BPD-MA LipoeQmee The following experiment of photodynamic therapy using a liposomal preparation of BPD-MA was conducted to determine the optimal time interval after intravenous injection as a bolus of the BPD-MA over about 20 seconds, followed by a 3-5 cc saline flush, to begin the irradiating step. Choroidal neovascularization in cynomolgus monkeys was treated to demonstrate efficacy of the photodynamic therapy. Normal chorcid tissue was treated to assess relative damage to adjacent tissues.
The monkeys were initially injected with a green porphyrin dose of 1 mg/kg. At predeterinined time intervals following this injection, the eyes of the monkeys were irradiated with an irradiance of 600 mW/cmZ, and a fluence of 150J/cm2. The irradiating light was from an argon/dye laser (Coherent 920 Coherent Medical Laser, Palo Alto, CA) equipped with a.200 micron fiber adapted through a LaserLink*(Coherent * Medical Laser) and a split lamp delivery system (Coherent). Other than these differences, the eye membranes were treated in the same manner as described in Example I. A11 areas of zreated choroidal neovasculature for all time points after the liposomal BPD-MA injection showed whitening of the retina and early hypofluorescense on fluorescein angiography when measured one week after treatment. On histology, there was evidence of partial closure of choroidal neovasculature at the early time points, no effect at mid-time points, and more effective closure at late irradiation time points, e.g., at 80 and 100 minutes.
The normal choroid treated with the same parameters showed whitening of the retina, early hypofluorescence at all time points, and histologic Trade-mark evidence of choroicapillaris (c-c) accompanied by damage to the choroid and retina, particularly at early time points.
Example 4 lZsincr PDT with BPD-MA Liposomes at Lower Green Por-phvrin Doses Using the general procedure of Example 1, additional experiments were performed using the intravenous injection of liposomal BPD-MA at doses of 0.25, 0.5 and 1 mg/kg. Photodynamic therapy was performed with an irradiance of_600 mW/cm2 , a fluence of 150 J/ctn2, and a treatment duration of four minutes, nine seconds.
The effects of treatment were assessed by fundus photography and fluorescein angiography, and then confirmed by light and electron microscopy. Photodynamic therapy of normal choroid tissue demonstrated the effect on adjacent structures, such as the retina, while the treatment of choroid neovascular tissue demonstrated efficacy.
Table 3 below describes the lesions produced on normal choroids by administration of 0.5 mg/kg BPD-MA at time points ranging from 5 to 60 minutes:
TABLE 3 - 0.5 mg/kct, NORMAL CHOROID
Time after injection Fluorescein (min) Anaioaraphy Histologv 5 Hypofluorescence c-c and large choroidal vessel closure; outer and inner retina damage.
20 Hypofluorescence; cc closure; damage retinal vessels - to outer retina normal 40 Mild early cc open (not center hypofluorescence of lesion); outer retina damage 60 Early cc closed; outer hypofluorescence; retina damage;
-less than the 20- inner.retina fairly minute lesion good.
described above When 0.5 mg/kg BPD-MA was also used to treat choroidal neovasculature under the same conditions, marked hypofluorescence corresponding to closure of choroid neovasculature was exhibited in areas irradiated at times of 5, 20 and 40 minutes after injection. When 50 minutes after injection were allowed to elapee before photodynamic irradiation was begun, therewas less hypofluorescence and presumabl.y less effective closure.
The study was then repeated with the green porphyrin dose decreased to 0.25 mg/kg. Table.4 below describes.the lesions produced on normal choroids by treatments with 0.25 mg/kg, 600 mW/cm7, and 150 J/cm2 at time points ranging from 5 to 60 minutes:
TABLE 4 - 0,25 ma/ka, NORMAL CHOROID
Time after injection Fluorescein (min) Angiography Histoloav 10 Early c-c closure;
hypofluorescence choroidal vessel -normal; RPE
damaged; retinal vessels - normal;
mild damage to outer retina 20 Early Same as 10-minute hypofluorescence lesion above 40 Faint early Patchy cc closure;
hypofluorescence; less damage to RPE
late staining and outer retina 60 Not demonstrated No effect on cc;
mild vacuolization of RPE
When the above study was repeated using the same green porphyrin dose of 0.25 mg/kg and irradiance of 600 mW/cm2, but with a reduced fluence of 100 J/cmZ, the same angiographic and histologic pattern was exhibited as described above. However, cc was open in the 40-minute lesion. - -In the last portion of these experimente, a green porphyrin dose of 0.25 mg/kg was used to treat experimental choroidal neovascularization with an irradiance of 600 mW/cmZ and a fluence of 150 J/cm2 at elapsed time points ranging from 5 to 100 minutes. This combination of conditions caused effective cc closure with only minimal damage to the outer retina. The results are shown in Table 5 below:
TABLE 5 - 0,25 ma/kgr PDT over CNV
Time after injection Fluorescein (min ) Angioaratahv Histoloay 5 Early Partially closed hypofluorescence CNV; c-c closed;
damage to inner retina 20 Early CNV - open vessel, hypofluorescence; fibrin and clots;
less than the 5- inner retina looks minute lesion fine 30 Some Minimal effect on hypofluorescense cNV
next to CNV
Hypofluorescence; Minimal effect on questionable change CNV
35 compared to previous reaction 60 Hypofluorescence Minimal effect on CNV
80 Hypofluorescence Partial closure of CNV; retina over-CNV looks intact 100 Hypofluorescence CNV partially closed Thus, fluorescein angiography and histopathology in the above series of experiments demonstrated early hypofluorescence at early time points.
Further, the histopathology study showed partial CNV
closure at all time points after injection using 80 and 100 minutes as the post-injection interval before the irradiating treatment.
In summary, acceptable destruction of choroidal neovascular tissue at all tested doses of BPD-:MA was shown by fluorescein angiography and_histology. However, the lower doses appeared to increase selectivity, as assessed by treatment of a normal choroid. Effective choriocapillaris closure in normal choroids with minimal retinal damage was produced by irradiating at a time about 10 minutes, 20 seconds after injection of the green porphyrin at a dose of 0.25 mg/kg. By adjusting the dose, the time of irradiation after green porphyrin injection, and fluence, one can improve even further_the selectivity of the green porphyrin. However, the liposomal preparation of BPD-MA was clearly demonstrated to be a potent photosensitizer.
Claims (8)
1. A porphyrin dye for use with light having an irradiance of about 600 mW/cm2 to treat unwanted choroidal neovasculature, the light being absorbed by the porphyrin dye.
2. The porphyrin dye according to claim 1, wherein the porphyrin dye is green porphyrin.
3. The porphyrin dye according to claim 1, wherein the unwanted choroidal neovasculature is associated with age-related macular degeneration.
4. A green porphyrin dye for use with light having an irradiance of about 600 mW/cm2 to treat age-related macular degeneration, the light being absorbed by the porphyrin dye.
5. Use of a porphyrin dye and light having an irradiance of about 600 mW/cm2 for treatment of unwanted choroidal neovasculature, the light being absorbed by the porphyrin dye.
6. The use according to claim 5, wherein the porphyrin dye is green porphyrin.
7. The use according to claim 5, wherein the unwanted choroidal neovasculature is associated with age-related macular degeneration.
8. Use of a green porphyrin dye and light having an irradiance of about 600 mW/cm2 for treatment of age-related macular degeneration, the light being absorbed by the porphyrin dye.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2185644A CA2185644C (en) | 1994-03-14 | 1994-03-14 | Use of green porphyrins in ocular diagnosis and therapy |
PCT/US1994/002639 WO1995024930A1 (en) | 1994-03-14 | 1994-03-14 | Use of green porphyrins in ocular diagnosis and therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2185644A Division CA2185644C (en) | 1994-03-14 | 1994-03-14 | Use of green porphyrins in ocular diagnosis and therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2536069A1 CA2536069A1 (en) | 1995-09-21 |
CA2536069C true CA2536069C (en) | 2008-06-03 |
Family
ID=22242340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2185644A Expired - Lifetime CA2185644C (en) | 1994-03-14 | 1994-03-14 | Use of green porphyrins in ocular diagnosis and therapy |
CA002536069A Expired - Lifetime CA2536069C (en) | 1994-03-14 | 1994-03-14 | Use of green porphyrins in ocular diagnosis and therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2185644A Expired - Lifetime CA2185644C (en) | 1994-03-14 | 1994-03-14 | Use of green porphyrins in ocular diagnosis and therapy |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6813694A (en) |
CA (2) | CA2185644C (en) |
WO (1) | WO1995024930A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
JP3845469B2 (en) * | 1996-02-21 | 2006-11-15 | 明治製菓株式会社 | Administration agent for occlusion of neovascularization of the fundus |
US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
WO1997035617A1 (en) * | 1996-03-26 | 1997-10-02 | Pharmacyclics, Inc. | Use of a texaphyrin in photodynamic therapy of pigment-related lesions |
US6043237A (en) * | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
KR20000057532A (en) * | 1996-12-11 | 2000-09-25 | 다우 윌리엄스 씨. | Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy |
US6022526A (en) * | 1997-07-30 | 2000-02-08 | Pharmacyclics, Inc. | Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
WO2001017561A1 (en) * | 1999-09-10 | 2001-03-15 | Akorn, Inc. | Fluorescent dye angiography and dye-enhanced photocoagulation |
US6351663B1 (en) | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
US6944493B2 (en) | 1999-09-10 | 2005-09-13 | Akora, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US6443976B1 (en) | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
EP1267935A2 (en) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
AU2006203034B2 (en) * | 2000-02-10 | 2006-09-07 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US7125542B2 (en) * | 2000-02-10 | 2006-10-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
CA2437557C (en) * | 2001-02-06 | 2012-07-24 | Qlt Inc. | Reduced total fluence photodynamic therapy of choroidal neovasculature in amd |
US7753943B2 (en) | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
OA12720A (en) * | 2001-11-09 | 2006-06-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases. |
US6723750B2 (en) | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
CA2500877A1 (en) | 2002-10-03 | 2004-04-15 | Light Sciences Corporation | Excitation of photoreactive compounds in eye tissue |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171749A (en) * | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5214036A (en) * | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
-
1994
- 1994-03-14 CA CA2185644A patent/CA2185644C/en not_active Expired - Lifetime
- 1994-03-14 WO PCT/US1994/002639 patent/WO1995024930A1/en active Application Filing
- 1994-03-14 AU AU68136/94A patent/AU6813694A/en not_active Abandoned
- 1994-03-14 CA CA002536069A patent/CA2536069C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1995024930A1 (en) | 1995-09-21 |
CA2536069A1 (en) | 1995-09-21 |
AU6813694A (en) | 1995-10-03 |
CA2185644C (en) | 2011-04-12 |
CA2185644A1 (en) | 1995-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5707986A (en) | Angiographic method using green porphyrins in primate eyes | |
US6225303B1 (en) | Use of green porphyrins to treat neovasculature in the eye | |
CA2536069C (en) | Use of green porphyrins in ocular diagnosis and therapy | |
EP0894009B1 (en) | Improved vision through photodynamic therapy of the eye | |
EP0799055B1 (en) | Selective and non-invasive visualization or treatment of vasculature | |
Peyman et al. | Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2) | |
JP2003519670A (en) | New treatments for eye diseases | |
EP1262179A1 (en) | Photodynamic therapy for selectively closing neovasa in eyeground tissue | |
US6524330B1 (en) | Method of ocular treatment | |
Moshfeghi et al. | Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies | |
Moshfeghi et al. | Fluorescence properties of a hydrophilic sensitizer in pigmented rats, rabbits, and monkeys | |
Levy et al. | Use Of Green Porphyrinsto Treat Neovasculature In The Eyes | |
AU705100C (en) | Improved vision through photodynamic therapy of the eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140314 |